First author, publication year No. of surgical patients Median followup, months Survival data Predictors of survival Mayo, 2011 [30 ] 339 [66 with simultaneous ablation] 26 Median OS: 123 months 5-year survival: 74% Symptomatic high-volume [>25% liver involved] disease benefited most from surgery (versus intra-arterial therapy,
) Saxena, 2011 [16 ] 74 [38 with simultaneous cryoablation] 41 Median PFS: 23 months Worse PFS with R1 (versus R0) pathologic margin status (
) Median OS: 95 months Worse OS from higher grade (well versus moderate versus poor differentiation,
) and extrahepatic disease (
) Karabulut, 2011 [31 ] 27 [excluding subsequent liver transplants] 29 Median PFS: 15 months Median OS: 190 months Margin status did not affect OS; in outcomes analysis including RFA and embolization, worse OS with male gender (
), dominant metastasis >5 cm (versus <3 cm,
), extrahepatic disease (
) Glazer, 2010 [32 ] 172 [120 with small bowel or pancreatic primaries; 18 had only RFA] 50 Median OS: 116 months 5-year survival: 77.4% 10-year survival: 50.4% Increasing time interval from primary resection to hepatic metastases predicted for poorer survival (
) Sarmiento, 2003 [8 ] 170 [75 with complete resection] Not reported (excluded <12 months followup) Median OS: 81 months 5-year survival: 61% 10-year survival: 35% No OS difference with or without endocrinopathy (60% versus 61% at 5 years,
), no OS difference between carcinoid and islet cell (87 versus 66 months,
) Elias, 2003 [33 ] 47 [36 with concurrent extrahepatic resection] 62 Median OS: 91 months 5-year survival: 71% 10-year survival: 35% Worse DFS with incomplete surgery (R2 versus R1 versus R0,
), pancreatic origin (
), bilateral liver involvement (
); no factor predicted OS Chen, 1998 [34 ] 15 27 5-year survival: 73% [versus 29% in 23 patients with unresectable disease] Median survival not reached in resection group, but OS significantly longer than unresected (
)
